GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Plandai Biotechnology Inc (OTCPK:PLPL) » Definitions » Debt-to-Revenue

Plandai Biotechnology (Plandai Biotechnology) Debt-to-Revenue : N/A (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Plandai Biotechnology Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Plandai Biotechnology's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.05 Mil. Plandai Biotechnology's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $0.00 Mil. Plandai Biotechnology's annualized Revenue for the quarter that ended in Jun. 2023 was $0.00 Mil.


Plandai Biotechnology Debt-to-Revenue Historical Data

The historical data trend for Plandai Biotechnology's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Plandai Biotechnology Debt-to-Revenue Chart

Plandai Biotechnology Annual Data
Trend Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 44.25 156.19 47.94 N/A N/A

Plandai Biotechnology Semi-Annual Data
Mar03 Mar04 Mar05 Mar06 Mar07 Mar08 Mar09 Mar10 Mar11 Jun12 Jun13 Jun14 Jun15 Jun16 Jun22 Jun23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.25 156.19 47.94 N/A N/A

Competitive Comparison of Plandai Biotechnology's Debt-to-Revenue

For the Shell Companies subindustry, Plandai Biotechnology's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Plandai Biotechnology's Debt-to-Revenue Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Plandai Biotechnology's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Plandai Biotechnology's Debt-to-Revenue falls into.



Plandai Biotechnology Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Plandai Biotechnology's Debt-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Plandai Biotechnology's annualized Debt-to-Revenue for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is one times the quarterly (Jun. 2023) Revenue data.


Plandai Biotechnology Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Plandai Biotechnology's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Plandai Biotechnology (Plandai Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
4811 49th Street, San Diego, CA, USA, 92115
Plandai Biotechnology Inc. manufactures highly bioavailable extracts from live plant materials.
Executives
Callum Baylis-duffield director FLAT 37 ISLAND HOUSE THREE MILL LANE, LONDON ENGLAND X0 E33AF
Timothy Matula other: Former Director 175 JACKSON AVE N, SUITE 102, MINNEAPOLIS MN 55343
Brian Johnson director P.O. BOX 1594, FERNDALE WA 98248-1594
Roger Duffield director, officer: President, Secretary and CFO 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
Daron Baylis Duffield director 2226 EASTLAKE AVENUE EAST #156, SEATTLE WA 98102
David Rzepnicki director 21 HORIZON DRIVE, SARATOGA SPRINGS NY 12866